Skip to content

Assessing the Sensitivity of SureTouch™ in Women Undergoing Diagnostic and Screening Mammography

Assessing the Sensitivity of SureTouch™ in Identifying Clinically Significant Masses in Women Undergoing Diagnostic and Screening Mammography

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04397029
Enrollment
213
Registered
2020-05-21
Start date
2019-01-04
Completion date
2021-02-10
Last updated
2022-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast, Screening, Elastography

Brief summary

Prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity.

Detailed description

This is a single-center, prospective, case-control study being conducted to determine the sensitivity of the SureTouch device in detecting known masses at a pre-determined level of specificity. Results of the mammography will be compared to the SureTouch examination results. Subjects will have between 1 and 3 research visits and 3 follow-up surveys, up to two years from the initial visit. The number of visits will be based upon comparison of the SureTouch examination to conventional breast screening techniques (mammogram and ultrasound).

Interventions

DEVICESureTouch

The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment. The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both. Both groups will receive breast cancer screening with mammography and SureTouch.

Sponsors

Sure, Inc.
CollaboratorINDUSTRY
George Washington University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Arm 1: * Female Subject presenting for screening mammography * 30-80 years of age, inclusive * Able to provide written informed consent Arm 2: * Female Subject presenting for diagnostic appointment and/or biopsy * 30-80 years of age, inclusive * 1-3 masses per breast * Masses between 0.5 cm and 3.5 cm only

Exclusion criteria

* Individuals who are unable to comprehend or unwilling to sign an informed consent form * Women younger than 30 or older than 80 * Pregnant women * Women who have undergone bilateral mastectomies * Males * Prisoners * Masses which are larger than 3.5 cm or smaller than 0.5 cm in size * Individuals with more than 3 masses per breast will be excluded due to the complexity of these cases

Design outcomes

Primary

MeasureTime frameDescription
Primary2 years1\. This study examines the sensitivity of the SureTouch™ system, compared with methods that are the current standard of care (screening and diagnostic mammography with ultrasound), to detect clinically significant mass lesions in the breast.

Secondary

MeasureTime frameDescription
Secondary2 yearsThe study will determine the patient acceptance of and satisfaction with the SureTouch devise. Outcome measure will use an original 8 question Likert-scale survey to assess patient perception of the comfort, duration, and acceptance of the device. A higher score indicates a better outcome. Brief Survey Monkey adapted from Press Ganey Patient Satisfaction Survey for Radiography and US Performed in the Outpatient Setting. Itri JN. Patient-centered Radiology. RadioGraphics 2015; 35:1835-1848

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026